TABLE 2.
Experimental studies of iron supplementation in healthy pregnant women in Europe1
| 32–39-wk test range |
||||||||||
| SF, μg/L |
ID, % (95% CI) |
IDA, % (95% CI) |
||||||||
| Study | Country | Sample, n | Study period, wk | Treatment, Fe2+ mg/d | C | Treatment | C | Treatment | C | Treatment |
| Milman et al. (51)2 | Denmark | IG1: 40; | 15 | IG1: 253 B; | NA | IG1: 21 (9, 58)4; | — | IG1: 14.85; | — | IG1: 06; |
| IG2: 40 | IG2: 507 D | IG2: 30 (8, 154)4 | IG2: 13.85 | IG2: 3.46 | ||||||
| Ribot et al. (42) | Spain | IG1: 169; | 10 | IG1: <608; | 7.7 (7.1, 8.3)4 | IG1: 9.3 (8.6, 10.0)4; | 81.5 (71.8, 91.2)4,9 | IG1: 70.3 (63.4, 77.2)4,9; | 35.2 (23.2, 47.2)4,7 | IG1: 22.2 (15.9, 28.5)4,6; |
| IG2: 38; | IG2: 60–1008; | IG2: 13.2 (12.6, 13.8)4; | IG2: 47.2 (31.3, 63.1)4,9; | IG2: 11.4 (1.3, 21.5)4,6; | ||||||
| IG3: 90; | IG3: >1008 | IG3: 14.9 (14.2, 15.6)4 | IG3: 37.6 (27.6, 47.6)4,9 | IG3: 14.6 (7.3, 21.9)4,6 | ||||||
| C: 61 | ||||||||||
| Milman et al. (52)10 | Denmark | IG1: 61; | 18 | IG1: 207; | NA | IG1: 15.5 ± 2.011; | — | IG1: 28.812; | — | IG1: 1013; |
| IG2: 66; | IG2: 407; | IG2: 22.4 ± 1.711; | IG2: 11.112; | IG2: 4.513; | ||||||
| IG3: 73; | IG3: 607; | IG3: 22.9 ± 1.711; | IG3: 10.012; | IG3: 013; | ||||||
| IG4: 69; | IG4: 807 | IG4: 26.9 ± 1.711 | IG4: 9.012 | IG4: 1.513 | ||||||
| Eskeland et al. (43) | Norway | HIG:24; NHIG: 25; C:20 | 20 | HIG: 3.6 mg Fe2+ heme and 24 mg Fe2+ 7; | — | — | 8514 | HIG: 2914; NHIG: 5214 | 415 | 015 |
| NHIG: 277 | ||||||||||
| Thomsen et al. (53)10 | Denmark | IG1: 22; | 16 | IG1: 1007; | — | IG1: 28.0 (19.0, 36.7)16; | IG2: 7217 | IG1: 517 | — | — |
| IG2: 21 | IG2: 1818 | IG2: 10.0 (8.5, 15.5)16 | ||||||||
| Milman et al. (44) | Denmark | IG: 100; | 12 | 6619 | 1220 | 2120 | 289 | 39 | 213 | 03 |
| C: 107 | ||||||||||
| Galan et al. (49) (in French) | France | IG: 81; | 12 | 4521 | 1022 | 1922 | 659 | 309 | — | 4 |
| C: 84 | ||||||||||
| Romslo et al. (45) | Norway | IG: 22; | 12 | 2007 | 6.0 ± 523 | 24.0 ±1323 | 8324 | 524 | — | — |
| C: 23 | ||||||||||
| Foulkes and Goldie (48) | United Kingdom | IG: 251; | 12 | 1007 | — | — | — | — | — | — |
| C: 250 | ||||||||||
| Taylor et al. (47) | United Kingdom | IG: 21; | 12 | 657 | 6 (2.5, 12.5)16 | 15.8 (7.0, 41.8)16 | — | — | — | — |
| C: 24 | ||||||||||
| Puolakka et al. (46) | Finland | IG: 16; | 16 | 2007 | 21 (12, 35)16 | 63 (43, 92)16 | — | — | — | — |
| C: 16 | ||||||||||
C, control group; HIG, heme iron group; ID, iron deficiency; IDA, iron deficiency anemia; IG, intervention group; NA, not applicable; NHIG, non–heme iron group; SF, serum ferritin.
Noninferiority study.
Ferrous-bisglycinate.
Geometric mean; 2.5th, 97.5th percentiles in parentheses.
SF concentration <15 μg/L.
Hemoglobin concentration <110 g/L and SF concentration <12 μg/L.
Ferrous sulfate.
Different iron compounds.
SF concentration <12 μg/L.
Dose-response study.
Geometric mean ± SD.
SF concentration <13 μg/L.
SF concentration <13 μg/L and hemoglobin concentration <6.6 mmol/L (106 g/L), 6.5 mmol/L (105 g/L), or 7.2 mmol/L (115 g/L).
SF concentration <11.5 μg/L.
Hemoglobin concentration <100 g/L and SF concentration <15 μg/L as determined through reported treatment failures.
Arithmetic mean; 2.5th, 97.5th percentiles in parentheses.
SF concentration <15 μg/L.
Ferrous fumarate in a multivitamin and multimineral tablet.
Ferrous fumarate.
Geometric mean derived from figure.
Ferrous betainate hydrochloride.
Geometric mean.
Arithmetic mean ± SD.
SF concentration <10 μg/L.